Rephonic
Artwork for Oncology Today

Oncology Today with Dr Neil Love

Dr. Neil Love
Immunotherapy
Clinical Trials
Breast Cancer
PARP Inhibitors
Antibody-Drug Conjugates
Ovarian Cancer
Prostate Cancer
Non-Hodgkin Lymphoma
Multiple Myeloma
Colorectal Cancer
CAR T-Cell Therapy
Chronic Lymphocytic Leukemia
Chemotherapy
Endometrial Cancer
Bispecific Antibodies
Follicular Lymphoma
Gastroesophageal Cancer
BTK Inhibitors
Non-Small Cell Lung Cancer
Metastatic Breast Cancer

Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.

PublishesDailyEpisodes424Founded6 years ago
Number of ListenersCategories
Health & FitnessScienceMedicine

Listen to this Podcast

Artwork for Oncology Today

Latest Episodes

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:

• Introduction (0:00)

• Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging U... more

Featuring perspectives from Dr Joyce F Liu, Dr David M O’Malley and Dr Brian M Slomovitz, moderated by Dr O’Malley, including the following topics:

• Introduction (0:00)

• Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr L... more

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:

• Introduction (0:00)

• Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)

• Noncovalent Bruton Tyrosine Kinase Inhibi... more

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:

• Introduction (0:00)

• Evolving Management of Nonmetastatic Hormone-... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Two Onc Docs
Two Onc DocsSam and Karine
ASCO Daily News
ASCO Daily NewsAmerican Society of Clinical Oncology (ASCO)

Recent Guests

Jennifer Brown
Faculty, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Episode: Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
Wojciech Jurczak
Faculty, Marie Curie National Research Institute of Oncology
Marie Curie National Research Institute of Oncology
Episode: Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
Ursula Matalonis
Dr
Dana-Farber Cancer Institute
Episode: Ovarian Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer
Jaffer Ajani
MD Anderson Cancer Center physician-scientist
MD Anderson Cancer Center
Episode: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Rutika Mehta
Weill Cornell Medical Center oncologist
Weill Cornell Medical Center
Episode: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Wassim Abida
Memorial Sloan Kettering Cancer Center
Episode: PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida
Jonathan Letterman
Professor, UCL Cancer Institute, London
University College London
Episode: Immunotherapy for Endometrial Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer
Ursula Matulonis
Dr., Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Episode: Immunotherapy for Endometrial Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer
Angela Secord
Dr., Duke Cancer Institute
Duke Cancer Institute
Episode: Immunotherapy for Endometrial Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer

Host

Neil Love
Multiple episode host with affiliations to Research To Practice and Oncology Today-related programs; central figure guiding many interviews.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#20
United Arab Emirates/Science
Apple Podcasts
#107
Saudi Arabia/Science
Apple Podcasts
#114
Hong Kong/Science
Apple Podcasts
#114
South Korea/Science
Apple Podcasts
#158
Japan/Science
Apple Podcasts
#195
India/Science

Talking Points

Recent interactions between the hosts and their guests.

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Q: What is your go-to frontline approach for MSI-H patients who are HER2 negative and Claudin 18.2 positive?
Use a regimen that prioritizes immunotherapy for response durability, typically nivolumab-based combinations when feasible, with pembrolizumab or nivolumab alone as alternatives depending on tolerance and biomarkers.
Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Q: What are the key practical takeaways for implementing ctDNA guidance in neoadjuvant and adjuvant settings based on the Niagara and MVIGR data?
ctDNA can identify patients who would benefit from early immune therapy and potentially spare those who are ctDNA negative from unnecessary exposure; in neoadjuvant settings, ctDNA dynamics help decide when to start/continue immunotherapy, with clearance indicating favorable prognosis.
Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Q: How would you conceptually compare the use of ctDNA in urothelial/bladder cancer to the current PSA relapse paradigm in other cancers?
ctDNA offers a dynamic, quantitative measure that can stratify relapse risk beyond traditional imaging, much like PSA in prostate cancer, but with the added complexity of multiple ctDNA clones and varying clearance kinetics that guide when to start or intensify therapy.
Oncology Nursing Update: Nonmelanoma Skin Cancers — An Interview with Dr Nikhil Khushalani
Q: How do you approach combining hedgehog inhibitors with immunotherapy in basal cell carcinoma?
The typical approach is upfront hedgehog inhibition, with immunotherapy considered if patients are intolerant or progress. Emerging data suggest potential sequencing strategies, and trials are exploring combinations, though results so far have not shown clear synergistic benefits in this setting.
Oncology Nursing Update: Nonmelanoma Skin Cancers — An Interview with Dr Nikhil Khushalani
Q: What are the key toxicity considerations with checkpoint inhibitors in this patient population?
Autoimmune toxicities are a major consideration but are generally manageable. Common side effects include fatigue, rash, diarrhea, and thyroid dysfunction; severe toxicities like myocarditis or endocrine crises are rare but require rapid recognition and management, often with steroids or immunosuppressants as needed.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Oncology Today

What is Oncology Today about and what kind of topics does it cover?

Medical oncology-focused conversations feature in-depth interviews and panel discussions with leading cancer researchers and clinicians. Episodes emphasize practical decision-making in biomarker-driven therapy, targeted agents, immunotherapy, and emerging diagnostic technologies, often anchored by real patient cases and community oncologist perspectives. Across samples, themes include PARP inhibitors in prostate cancer, ctDNA/MRD-guided colorectal cancer strategies, and the integration of novel agents (e.g., CELMoDs, antibody-drug conjugates) into front-line and relapse settings. Notable is the strong emphasis on translating trial data into everyday practice, including testing strategies, sequencing decisions, toxicity management, and the e... more

Where can I find podcast stats for Oncology Today?

Rephonic provides a wide range of podcast stats for Oncology Today. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Oncology Today and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Oncology Today get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Oncology Today, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Oncology Today?

Rephonic provides comprehensive predictive audience data for Oncology Today, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Oncology Today have?

To see how many followers or subscribers Oncology Today has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Oncology Today?

These podcasts share a similar audience with Oncology Today:

1. Two Onc Docs
2. ASCO Daily News
3. Research To Practice | Oncology Videos
4. Oncology Brothers: Practice-Changing Cancer Discussions
5. Breast Cancer Update

How many episodes of Oncology Today are there?

Oncology Today launched 6 years ago and published 424 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Oncology Today?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Oncology Today?

Rephonic pulls ratings and reviews for Oncology Today from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Oncology Today?

Rephonic provides full transcripts for episodes of Oncology Today. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Oncology Today?

Recent guests on Oncology Today include:

1. Jennifer Brown
2. Wojciech Jurczak
3. Ursula Matalonis
4. Jaffer Ajani
5. Rutika Mehta
6. Dr Wassim Abida
7. Jonathan Letterman
8. Ursula Matulonis

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days